Cargando…

Nuclear Morphological Characteristics in Breast Cancer: Correlation with Hormone Receptor and Human Epidermal Growth Factor Receptor 2

BACKGROUND: Hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the common diagnostic/prognostic markers in breast cancer. Few articles have recently reported the correlation between cytology and molecular subtypes. We combined nuclear morphological characteristics with HR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Jiayu, Zhou, Yehan, Li, Yunzhu, Liu, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604609/ https://www.ncbi.nlm.nih.gov/pubmed/34804778 http://dx.doi.org/10.1155/2021/3037993

Ejemplares similares

The Novel Role of Cytomorphology from Ultrasound-Guided Fine Needle Aspiration Cytology in Evaluating the Status of Prognostic Factors including Estrogen Receptor, Progesterone Receptor and HER2 in Breast Cancer
por: Li, Yunzhu, et al.
Publicado: (2022)

Correlation of Hormone Receptor and Human Epidermal Growth Factor Receptor-2/neu Expression in Breast Cancer with Various Clinicopathologic Factors
por: Bansal, Cherry, et al.
Publicado: (2017)

Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain
por: Duchnowska, Renata, et al.
Publicado: (2012)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

Nuclear localization of epidermal growth factor receptor (EGFR) in ameloblastomas
por: Pereira, Núbia Braga, et al.
Publicado: (2015)

Nuclear epidermal growth factor receptor as a therapeutic target
por: Atwell, Benjamin, et al.
Publicado: (2023)

Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer
por: Alataki, Anastasia, et al.
Publicado: (2022)

Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
por: Li, Junjie, et al.
Publicado: (2019)

The role of p21/CIP1/WAF1 (p21) in the negative regulation of the growth hormone/growth hormone receptor and epidermal growth factor/epidermal growth factor receptor pathways, in growth hormone transduction defect
por: Kostopoulou, Eirini, et al.
Publicado: (2018)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Brufsky, Adam M.
Publicado: (2015)

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Avila, Jorge, et al.
Publicado: (2023)

Epidermal growth factor receptor in glioblastoma
por: Xu, Hongsheng, et al.
Publicado: (2017)

Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells
por: Watt, Heather L, et al.
Publicado: (2006)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
por: Iida, Mari, et al.
Publicado: (2012)

The role of ultrasonographic findings for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer
por: Li, Shuo, et al.
Publicado: (2023)

Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family
por: Wang, Ying-Nai, et al.
Publicado: (2012)

Attribution to Heterogeneous Risk Factors for Breast Cancer Subtypes Based on Hormone Receptor and Human Epidermal Growth Factor 2 Receptor Expression in Korea
por: Park, Boyoung, et al.
Publicado: (2016)

Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
por: Shen, Le-Sang, et al.
Publicado: (2020)

Hormonal Receptors, Human Epidermal Growth Factor Receptor-2 and Triple Negative Immunohistochemical Typing in Women with Breast Cancer in Kampala, Uganda
por: Mlole, Angela T, et al.
Publicado: (2020)

Epidermal growth factor receptor and oestrogen receptors in the non-malignant part of the cancerous breast.
por: Barker, S., et al.
Publicado: (1989)

Targeting the epidermal growth factor receptor
por: El-Rayes, B F, et al.
Publicado: (2004)

Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report
por: Yue, Li, et al.
Publicado: (2020)

A Validation Study of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry Digital Imaging Analysis and its Correlation with Human Epidermal Growth Factor Receptor 2 Fluorescence In situ Hybridization Results in Breast Carcinoma
por: Hartage, Ramon, et al.
Publicado: (2020)

Human Epidermal Growth Factor Receptor 2 and Estrogen Receptor Status in Respect to Tumor Characteristics in Non-Metastatic Breast Cancer
por: Mirtavoos-Mahyari, Hanifeh, et al.
Publicado: (2014)

Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival
por: Jeon, Ye Won, et al.
Publicado: (2015)

Patients’ preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan
por: Omori, Yukie, et al.
Publicado: (2019)

Porcine growth hormone induces the nuclear localization of porcine growth hormone receptor in vivo
por: Lan, Hainan, et al.
Publicado: (2018)

Correlation between the overexpression of epidermal growth factor receptor and mesenchymal makers in endometrial carcinoma
por: Yang, Wei-Ning, et al.
Publicado: (2014)

Epidermal growth factor receptors in intracranial and breast tumours: their clinical significance.
por: Hawkins, R. A., et al.
Publicado: (1991)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)

Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor–Positive Human Epidermal Growth Factor Receptor-2–Negative Early Breast Cancer Without Chemotherapy
por: Fu, Fangmeng, et al.
Publicado: (2022)

Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients
por: Ge, Wen-kai, et al.
Publicado: (2015)

The diagnostic value of BI-RADS grade 3 to 5 for breast masses is correlated with the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2
por: He, Tiejun, et al.
Publicado: (2023)

Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Zhang, Hui-Qiang, et al.
Publicado: (2021)

Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer
por: Murata, Takeshi, et al.
Publicado: (2023)

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers
por: Migliaccio, Ilenia, et al.
Publicado: (2015)

Elevated tumor mutation burden and immunogenic activity in patients with hormone receptor-negative or human epidermal growth factor receptor 2-positive breast cancer
por: Xu, Junnan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rru8fotqk86m3kpmqb840i9n9q